Role of C-Reactive Protein in Cardiovascular Disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To discuss the role of C-reactive protein (CRP) in cardiovascular disease as a predictor of vascular events and identify key factors that increase or decrease this inflammatory marker. DATA SOURCES: Articles were identified through searches of MEDLINE (1966–July 2003), International Pharmaceutical Abstracts (1970–June 2003), and bibliographies of selected articles. Search terms included C-reactive protein, HMG-CoA reductase inhibitors, fenofibrate, niacin, aspirin, estrogen, thiazolidinediones, and raloxifene. DATA SELECTION AND DATA EXTRACTION: All studies relevant to CRP and cardiovascular disease or the effects of pharmacologic and nonpharmacologic interventions on CRP levels were evaluated. All information deemed relevant to this review was included. DATA SYNTHESIS: Numerous studies have shown a strong association between CRP levels and future vascular events (i.e., coronary, cerebrovascular, peripheral vascular disease), with minimal correlation to low-density-lipoprotein cholesterol. Clinical guidelines have recently been published indicating that CRP levels of <1, 1–3, and >3 mg/L correspond to low, moderate, and high risk, respectively, for future vascular events. Drugs including statins, fibrates, niacin, thiazolidinediones, and antiplatelet agents, as well as weight loss and exercise, have demonstrated efficacy in lowering CRP levels. CONCLUSIONS: CRP appears to be a valuable tool for predicting future vascular events in patients striving for primary or secondary prevention of cardiovascular disease. While several pharmacologic and nonpharmacologic interventions have been shown to lower CRP levels, the impact on clinical outcomes requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488
Ridker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Tracy, R. P., Lemaitre, R. N., Psaty, B. M., Ives, D. G., Evans, R. W., Cushman, M., Meilahn, E. N., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1121 · Cited by 836
Cushman, M., Legault, C., Barrett-Connor, E., Stefanick, M. L., Kessler, C., Judd, H. L., Sakkinen, P. A., & Tracy, R. P. (1999) · Circulation · doi:10.1161/01.cir.100.7.717 · Cited by 660
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women
Tchernof, A., Nolan, A., Sites, C. K., Ades, P. A., & Poehlman, E. T. (2002) · Circulation · doi:10.1161/hc0502.103331 · Cited by 541
Lipids, risk factors and ischaemic heart disease
Castelli, W. P. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05851-0 · Cited by 337
Heilbronn, L. K., Noakes, M., & Clifton, P. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.6.968 · Cited by 331
Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B., & Jialal, I. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00156-6 · Cited by 153
Cited by
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Obesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 272
Yildiz, M. F., Kumru, S., Godekmerdan, A., & Kutlu, S. (2005) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2005.05.005 · Cited by 56
“Thus, measuring hs-CRP levels has been suggested for the prediction of cardiovascular events [13,14].”
MethodGuo, Z., Wu, Y., Zhu, L., Wang, Y., Wang, D., & Sun, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00908-1 · Cited by 9
“It is a nonspecific acute phase reactant that has traditionally been used to detect acute injury, infection and inflammation[25].”
Background
Metadata
- Authors
- Backes, J. M., Howard, P. A., & Moriarty, P. M.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2004-01
- Volume
- 38
- Issue
- 1
- Pages
- 110-118
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2141093922
- Cited by
- 83
- References
- 14
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.